EUVIMEDEUVIMED entdecken
Crossref

Cardiovascular Disease in Anabolic Androgenic Steroid Users

Josefine Windfeld-Mathiasen iD, Ida M Heerfordt iD, Kim Peder Dalhoff iD, Jon Trærup Andersen, Michael Asger Andersen iD, Karl Sebastian Johansson iD, Tor Biering-Sørensen iD, Flemming Javier Olsen iD, Henrik Horwitz iD

Circulation · 25.03.2025 · 151 (12) · 828-834

DOI: 10.1161/circulationaha.124.071117 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Circulation, erschienen am 25.03.2025. Verfasst von Josefine Windfeld-Mathiasen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark (J.W.-M., I.M.H., K.P.D., J.T.A., M.A.A., K.S.J., H.H…. Hauptthemen laut MEDLINE: Cardiovascular Diseases, Anabolic Agents, Androgens, Testosterone Congeners. Die Arbeit wurde bisher 73-mal zitiert (Crossref) und nennt 44 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Use of anabolic androgenic steroids (AASs) is associated with increased mortality, and case reports have suggested that some of these deaths are due to cardiovascular disease. However, the epidemiology of cardiovascular disease in AAS users is still relatively unexplored. This study aimed to measure the incidence of cardiovascular disease in male AAS users and to compare these rates with those of a cohort from the general population matched by age and sex. METHODS: Men sanctioned in an antidoping program for AAS use in Danish fitness centers between 2006 and 2018 were included and matched for age and sex with 50 times as many controls from the general Danish population. The cohort was followed until June 30, 2023. Using the nationwide registries, we obtained information on admissions, prescriptions, educational length, and occupational status for both the AAS users and controls. This study investigated the incidence of acute myocardial infarction, percutaneous coronary intervention, or coronary artery bypass graft, venous thromboembolism, ischemic stroke, arrhythmia, cardiomyopathy, heart failure, and cardiac arrest during the follow-up period. RESULTS: During an average of 11 years of follow-up, AAS users (n=1189) demonstrated a significantly higher incidence of several cardiovascular events compared with controls (n=59 450). Correspondingly, AASs were associated with an increased risk of acute myocardial infarction (adjusted hazard ratio [aHR] 3.00 [95% CI, 1.67–5.39]), percutaneous coronary intervention or coronary artery bypass graft (aHR 2.95 [95% CI, 1.68–5.18]), venous thromboembolism (aHR 2.42 [95% CI, 1.54–3.80]), arrhythmias (aHR 2.26 [95% CI, 1.53–3.32]), cardiomyopathy (aHR 8.90 [95% CI, 4.99–15.88]), and heart failure (aHR 3.63 [95% CI, 2.01–6.55]). Due to the limited number of ischemic stroke and cardiac arrest cases among AAS users, these outcomes were not reportable. CONCLUSIONS: AAS use is associated with a substantially increased risk of cardiovascular disease in a large cohort with a long follow-up period.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cardiovascular DiseasesAnabolic AgentsAndrogensTestosterone CongenersHumansMaleMiddle AgedDenmarkAdultIncidenceRegistriesAgedRisk FactorsAnabolic Androgenic Steroids

Stichwörter der Autor:innen

anabolic androgenic steroidscardiovascular diseasescohort studydopingtestosterone

Substanzen

Anabolic AgentsAndrogensTestosterone CongenersAnabolic Androgenic Steroids

Autor:innen und Institutionen

  • Department of Clinical Pharmacology, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark (J.W.-M., I.M.H., K.P.D., J.T.A., M.A.A., K.S.J., H.H.).
  • Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark (J.W.-M., K.P.D., J.T.A., H.H.).
  • Center for Translational Cardiology and Pragmatic Randomized Trials, Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark (T.B.S., F.J.O.).
  • Cardiovascular Non-Invasive Imaging Research Laboratory, Department of Cardiology, Copenhagen University Hospital - Herlev and Gentofte, Denmark (T.B.S., F.J.O.).
  • Steno Diabetes Center Copenhagen, Copenhagen, Denmark (T.B.S.).
  • Department of Cardiology, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark (T.B.S.).

ORCID-Profile: Josefine Windfeld-Mathiasen, Ida M Heerfordt, Kim Peder Dalhoff, Michael Asger Andersen, Karl Sebastian Johansson, Tor Biering-Sørensen, Flemming Javier Olsen, Henrik Horwitz

Zitieren

APA

Windfeld-Mathiasen, J., Heerfordt, I. M., Dalhoff, K. P., Andersen, J. T., Andersen, M. A., Johansson, K. S., Biering-Sørensen, T., Olsen, F. J., & Horwitz, H. (2025). Cardiovascular Disease in Anabolic Androgenic Steroid Users. Circulation, 151(12), 828-834. https://doi.org/10.1161/circulationaha.124.071117

Vancouver

Windfeld-Mathiasen J, Heerfordt IM, Dalhoff KP, Andersen JT, Andersen MA, Johansson KS, et al. Cardiovascular Disease in Anabolic Androgenic Steroid Users. Circulation. 2025;151(12):828-834. doi:10.1161/circulationaha.124.071117

BibTeX
@article{WindfeldMathiasen2025,
  author = {Windfeld-Mathiasen, Josefine and Heerfordt, Ida M and Dalhoff, Kim Peder and Andersen, Jon Trærup and Andersen, Michael Asger and Johansson, Karl Sebastian and Biering-Sørensen, Tor and Olsen, Flemming Javier and Horwitz, Henrik},
  title = {Cardiovascular Disease in Anabolic Androgenic Steroid Users},
  journal = {Circulation},
  year = {2025},
  volume = {151},
  number = {12},
  pages = {828--834},
  doi = {10.1161/circulationaha.124.071117}
}
Kostenlos starten →